Rank in 2013: 6th
Community Size: 3rd
Activity: 4th
Engagement: 3rd
Virality: 4th

Another growing social media connectivity master, Novartis ($NVS) climbed in Ogilvy's rankings with high scores across all the connected categories. With one of the bigger audiences in the industry, Novartis would seem to have an advantage, but Ogilvy's weighted system means even big audiences need to be active to count for engagement and virality.

Novartis is most active on Twitter and Facebook, including posting YouTube videos that include scientists sharing views, executives talking about financial results and patients discussing their conditions. Novartis often singles out on its social media one of the more than 40 rare diseases its scientists are working on. In the past year that has included the hormonal disease acromegaly, genetic tumor disease TSC (tuberous sclerosis complex), and blood cancer polycythemia vera, with patient views and stories on each.

Novartis uses different Twitter tactics to engage consumers there, including twitterviews, or interviews conducted on Twitter, such as interviewing the Women Heart organization on heart failure at #HFtwitterview. It's also done several tweetchats including one hashtagged  #MYDCchat (Make Your Dialogue Count) encouraging advanced breast cancer patients to make conversations with their doctors count, and another on diabetes hashtagged #Time2DoMore. Time 2 Do More is the name of the marketing program to support Type 2 diabetes patients that also includes YouTube videos, custom surveys and a web-distributed infographic.

For more:
For Entresto rollout, Novartis marketing mixes tried-and-true with new-and-different
Novartis' Sandoz puts India plant on chopping block
Novartis' pay-for-performance Entresto plan has its critics--Express Scripts' Miller among them
UPDATED: Novartis nabs early FDA approval for 'megablockbuster' Entresto
Novartis steps into wearables with app for Apple Watch, Android Wear


Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.